Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: Response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1946-1954

  Chang, Thomas K H ^a,b   Yu, Li ^a   Maurel, Patrick ^c   Waxman, David J ^a  

^a Boston University   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IFOSFAMIDE; OXAZAPHOSPHORINE DERIVATIVE; PRODRUG; RIFAMPICIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG ACTIVATION; DRUG HYDROXYLATION; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; LIVER CELL CULTURE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOTRANSFORMATION; CELLS, CULTURED; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ENZYME INDUCTION; FEMALE; HUMANS; HYDROXYLATION; IFOSFAMIDE; ISOENZYMES; KINETICS; LIVER; MALE; MIDDLE AGED; PHENOBARBITAL; PRODRUGS; RIFAMPIN;

EID: 0030951908     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Moore, M. J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet., 20: 194-208, 1991.
2. Dechant, K. L., Brogden, R. N., Pilkington, T., and Faulds, D. Ifosfamide/mesna: a review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs, 42: 428-467, 1991.
3. Sladek, N. E. Metabolism of oxazaphosphorines. Pharmacol. Ther., 37: 301-355, 1988.
4. Chang, T. K. H., Weber, G. F., Crespi, C. L., and Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res., 53: 5629-5637, 1993.
5. Walker, D., Flinois, J. P., Monkman, S. C., Beloc, C., Boddy, A. V., Cholerton, S., Daly, A. K., Lind, M. J., Pearson, A. D. J., Beaune, P. H., and Idle, J. R. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol., 47: 1157-1163, 1994.
6. m catalysts of cyclophosphamide and ifosfamide activation., Pharmacogenetics, in press, 1997.
7. Boos, J., Welslau, U., Ritter, J., Blaschke, G., and Schellong, G. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother. Pharmacol., 28: 455-460, 1991.
8. 31P nuclear magnetic resonance spectroscopy. J. Pharmacol. Exp. Ther., 260: 1133-1144, 1992.
9. Granvil, C. P., Ducharme, J., Leyland-Jones, B., Trudeau, M., and Wainer, I. W. Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemother. Pharmacol., 37: 451-156, 1996.
10. Yu, L., and Waxman, D. J. Role of cytochrome P450 in oxazaphosphorine metabolism: deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver P450s. Drug Metab. Dispos., 24: 1254-1262, 1996.
11. Goren, M. P., Wright, R. K., Pratt, C. B., and Pell, F. E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet, 2: 1219-1220, 1986.
12. Wainer, I. W., Ducharme, J., Granvil, C. P., Trudeau, M., and Leyland-Jones, B. Ifosfamide stereoselective dichloroethylation and neurotoxicity. Lancet, 343: 982-983, 1994.
13. Sladek, N. E., Doeden, D., Powers, J. F., and Krivit, W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rep., 68: 1247-1254, 1984.
14. Boddy, A. V., Furtun, Y., Sardas, S., Sardas, O., and Idle, J. R. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J. Natl. Cancer Inst., 84: 1744-1748, 1992.
15. Yule, S. M., Boddy, A. V., Cole, M., Price, L., Wyllie, R., Tasso, M. J., Pearson, A. D. J., and Idle, J. R. Cyclophosphamide pharmacokinetics in children. Br. J. Clin. Pharmacol., 41: 13-19, 1996.
16. Lewis, L. D., Fitzgerald, D. L., Harper, P. G., and Rogers, H. J. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br. J. Clin. Pharmacol., 30: 725-732, 1990.
17. Kurowski, V., and Wagner, T. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother. Pharmacol., 33: 36-42, 1993.
18. Boddy, A. V., Proctor, M., Simmonds, D., Lind, M. J., and Idle, J. R. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur. J. Cancer, 31A: 69-76, 1995.
19. Jao, J. Y., Jusko, W. J., and Cohen, J. L. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res., 32: 2761-2764, 1972.
20. Faber, O. K., Mouridsen, H. T., and Skovsted, L. The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol. Toxicol., 35: 195-200, 1974.
21. Ayash, L. J., Wright, J. E., Tretyakov, O., Gonin, R., Elias, A., Wheeler, C., Eder, J. P., Rosowsky, A., Antman, K., and Frei, E., III. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J. Clin. Oncol., 10: 995-1000, 1992.
22. Bagley, C. M., Jr., Bostick, F. W., and DeVita, V. T., Jr. Clinical pharmacology of cyclophosphamide. Cancer Res., 33: 226-233, 1973.
23. Graham, M. I., Shaw, I. C., Souhami, R. L., Sidau, B., Harper, P. G., and McLean, A. E. Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother. Pharmacol., 10: 192-193, 1983.
24. Schuler, U., Ehninger, G., and Wagner, T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother. Pharmacol., 20: 248-252, 1987.
25. Nelson, R. L., Allen, L. M., and Creaven, P. J. Pharmacokinetics of divided-dose ifosfamide. Clin. Pharmacol. Ther., 19: 365-370, 1975.
26. Lind, M. J., Margison, J. M., Cerny, T., Thatcher, N., and Wilkinson, P. M. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res., 49: 753-757, 1989.
27. Moore, M. J., Hardy, R. W., Thiessen, J. J., Soldin, S. J., and Erlichman, C. Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin. Pharmacol. Ther., 44: 622-628, 1988.
28. Fasola, G., Lo Greco, P., Calori, E., Zilli, M., Verlicchi, F., Motta, M. R., Ricci, P., Baccarani, M., and Tura, S. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation. Haematologica, 76: 120-125, 1991.
29. Sladek, N. E., Priest, J., Doeden, D., Mirocha, C. J., Pathre, S., and Krivit, W. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat. Rep., 64: 1061-1066, 1980.
30. LeBlanc, G. A., and Waxman, D. J. Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Res., 50: 5720-5726, 1990.
31. Chang, T. K. H., and Waxman, D. J. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5α-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res., 53: 2490-2497, 1993.
32. McClure, M. T., and Stupans, I. Hormonal perturbation as a possible mechanism for the alteration of cytochrome P450 by cyclophosphamide. Biochem. Pharmacol., 49: 1827-1836, 1995.
33. Kraner, J. C., Morgan, E. T., Poet, T. S., Born, S. L., Burnett, V. L., and Halpert, J. R. Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity. J. Pharmacol. Exp. Ther., 276: 258-264, 1996.
34. Daujat, M., Pichard, L., Fabre, I., Pineau, T., Fabre, G., Bonfils, C., and Maurel, P. Induction protocols for cytochromes P450IIIA in vivo and in primary cultures of animal and human hepatocytes. Methods Enzymol., 206: 345-353, 1991.
35. Daujat, M., Pichard, L., Dalet, C., Larroque, C., Bonfils, C., Pompon, D., Li, D., Guzelian, P. S., and Maurel, P. Expression of five forms of microsomal cytochrome P-450 in primary cultures of rabbit hepatocytes treated with various classes of inducers. Biochem. Pharmacol., 36: 3597-3606, 1987.
36. Waxman, D. J., and Walsh, C. Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: purification, characterization, and interactions with metyrapone and cytochrome b5. Biochemistry, 22: 4846-4855, 1983.
37. Waxman, D. J. Rat hepatic cytochrome P-450 isoenzyme 2c. Identification as a male-specific, developmentally induced steroid 16α-hydroxylase and comparison to a female-specific cytochrome P-450 isoenzyme. J. Biol. Chem., 259: 15481-15490, 1984.
38. Waxman, D. J., Dannan, G. A., and Guengerich, F. P. Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry, 24: 4409-4417, 1985.
39. Curi-Pedrosa, R., Daujat, M., Pichard, L., Ourlin, J. C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., Fourtanier, G., and Maurel, P. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J. Pharmacol. Exp. Ther., 269, 384-392, 1994.
40. Waxman, D. J. Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes. Methods Enzymol., 206: 249-267, 1991.
41. Masurel, D., Houghton, P. J., Young, C. L., and Wainer, I. W. Efficacy, toxicity, pharmacokinetics, and in vitro metabolism of the enantiomers of ifosfamide in mice. Cancer Res., 50: 252-255, 1990.
42. Waxman, D. J. P450-catalyzed steroid hydroxylation: assay and product identification by thin-layer chromatography, Methods Enzymol., 206: 462-476, 1991.
43. Pichard, L., Fabre, I., Daujat, M., Domergue, J., Joyeux, H., and Maurel, P. Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes, Mol. Pharmacol. 41: 1047-1055, 1992.
44. Schuetz, E. G., Schuetz, J. D., Strom, S. C., Thompson, M. T., Fisher, R. A., Molowa, D. T., Li, D., and Guzelian, P. S. Regulation of human liver cytochromes P450 in family 3A in primary and continuous culture of human hepatocytes. Hepatology, 18: 1254-1262, 1993.
45. Kocarek, T. A., Schuetz, E. G., Strom, S. C., Fisher, R. A., and Guzelian, P. S. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab. Dispos., 23: 415-421, 1995.
46. Pichard, L., Fabre, I., Fabre, G., Domergue, J., Saint Aubert, B., Mourad, G., and Maurel, P. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos., 18: 595-606, 1990.
47. Boddy, A. V., Cole, M., Pearson, A. D., and Idle, J. R. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother. Pharmacol. 36: 53-60, 1995.
48. Boddy, A. V., Yule, S. M., Wyllie, R., Price, L., Pearson, A. D. J., and Idle, J. R. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother. Pharmacol., 38: 147-154, 1996.
49. Schuetz, J. D., Molowa, D. T., and Guzelian, P. S. Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. Arch. Biochem. Biophys., 274: 355-365, 1989.
50. Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. P., Meyer, U. A., Fischer, V., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., and Gonzalez, F. J. Cytochrome P450 hPCN3, a novel cytochrome P450IIIA gene product that is differentially expressed in adult human liver, cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem., 264: 10388-10395, 1989.
51. Wrighton, S. A., Ring, B. J., Watkins, P. B., and Vandenbranden, M. Identification of a polymorphically expressed member of the human cytochrome P450III family. Mol. Pharmacol., 36: 97-105, 1989.
52. Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., Gunsalus, I. C., and Nebert, D. W. P450 superfamily update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6: 1-42, 1996.
53. Morel, F., Beaune, P. H., Ratanasavanh, D., Flinois, J. P., Yang, C. S., Guengerich, F. P., and Guillouzo, A. Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur. J. Biochem., 191: 437-444, 1990.
54. Twum-Barima, Y., and Carruthers, S. G. Quinidine-rifampin interaction. N. Engl. J. Med., 304: 1466-1469, 1981.
55. Bolt, H. M., Bolt, M., and Kappus, H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol. (Copenh)., 85: 189-197, 1977.
56. Guengerich, F. P., Muller-Enoch, D., and Blair, I. A. Oxidation of quinidine by human liver cytochrome P-450. Mol. Pharmacol., 30: 287-295, 1986.
57. Guengerich, F. P. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol. Pharmacol. 33: 500-508, 1988.
58. Li, A. P., Rasmussen, A., Xu, L., and Kaminski, D. E. Rifampicin induction of lidocaine metabolism in cultured human hepatocytes. J. Pharmacol Exp. Ther., 274: 673-677, 1995.
59. Kostrubsky, V. E., Strom, S. C., Wood, S. G., Wrighton, S. A., Sinclair, P. R., and Sinclair, J. F. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch. Biochem. Biophys., 322: 516-520, 1995.
60. Acocella, G. Clinical pharmacokinetics of rifampicin. Clin. Pharmacokinet., 3: 108-127, 1978.
61. Mimura, M., Baba, T. Yamazaki, H., Ohmori, S., Inui, Y., Gonzalez, F. J., Guengerich, F. P., and Shimada, T. Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metab. Dispos., 21: 1048-1056, 1993.
62. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423, 1994.
63. Waxman, D. J., and Azaroff, L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J., 281: 577-592, 1992.
64. Zilly, W., Breimer, D. D., and Richter, E. Induction of drug metabolism in man after rifampicin treatment measured by increased hexobarbital and tolbutamide clearance. Eur. J. Clin. Pharmacol., 9: 219-227, 1975.
65. Heimark, L. D., Gibaldi, M., Trager, W. F., O'Reilly, R. A., and Goulart, D. A. The mechanism of the warfarin-rifampin drug interaction in humans. Clin. Pharmacol Ther., 42: 388-394, 1987.
66. Relling, M. V., Aoyama, T., Gonzalez, F. J., and Meyer, U. A. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther., 252: 442-447, 1990.
67. Doecke, C. J., Veronese, M. E., Pond, S. M., Miners, J. O., Birkett, D. J., Sansom, E. N., and McManus, M. E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br. J. Clin. Pharmacol., 31: 125-130, 1991.
68. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., and Trager, W. F. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol., 5: 54-59, 1992.
69. Chen, T. L., Passos-Coelho, J. L., Noe, D. A., Kennedy, M. J., Black, K. C., Colvin, O. M., and Grochow, L. B. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res., 55: 810-816, 1995.
70. Lind, M. J., Roberts, H. L., Thatcher, N., and Idle, J. R. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide. Cancer Chemother. Pharmacol., 26: 105-111, 1990.
71. Hartley, J. M., Hansen, L., Harland, S. J., Nicholson, P. W., Pasini, F., and Souhami, R. L. Metabolism of ifosfamide during a 3 day infusion. Br. J. Cancer, 69: 931-936, 1994.
72. Gentile, D. M., Tomlinson, E. S., Maggs, J. L., Park, B. K., and Back, D. J. Dexamethasone metabolism by human liver in vitro, metabolite identification and inhibition of 6-hydroxylation. J. Pharmacol. Exp. Ther., 277: 105-112, 1996.
73. Greuet, J., Pichard, L., Bonfils, C., Domergue, J., and Maurel, P. The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture. Biochem. Biophys. Res. Commun., 225: 689-694, 1996.